

QIAGEN Deep Dive – Sample technologies (1/2)



Thierry Bernard
Chief Executive Officer

Thierry Bernard joined QIAGEN in February 2015 to lead the company's growing presence in molecular diagnostics, the application of Sample to Insight solutions for molecular testing in human healthcare. He was named Chief Executive Officer in March 2020 after serving in this role on an interim basis and became a member of the Managing Board in 2021.

Previously, Mr. Bernard held roles of increasing responsibility during 15 years with bioMérieux SA, most recently as Corporate Vice President, Global Commercial Operations, Investor Relations and the Greater China Region, and held senior management roles in several other leading international companies. He was named Chair of the AdvaMedDx Board of Directors in March 2023, a U.S. industry trade association, and joined the Board of Directors of Neogen Corporation (NASDAQ: NEOG) in 2024.

Mr. Bernard has earned degrees and certifications from Sciences Po, the London School of Economics, the College of Europe, Harvard Business School, Centro de Comercio Exterior de Barcelona. He has been appointed Conseiller du Commerce Extérieur by the French government.



Nitin Sood
Senior Vice President
Head of Product Portfolio & Innovation

Nitin Sood joined QIAGEN in 2023 as Senior Vice President, Head of the Life Sciences Business Area, and member of the Executive Committee, and was named Head of Product Portfolio & Innovation in January 2025.

He most recently served as Chief Commercial Officer, MRD, at Adaptive Biotechnologies. He has enjoyed a 20-year career in the diagnostic and life science fields, having also held leadership roles at Guardant Health, PerkinElmer, Agilent Technologies and NuGEN Technologies.

He holds a Master's degree from Delhi University in Molecular Biology and a Master's degree from Ball State University in Computer Science.



Fernando Beils
Senior Vice President
Head of Global Commercial Operations

Fernando Beils joined QIAGEN in 2023 as Senior Vice President, Head of the Molecular Diagnostics Business Area, and member of the Executive Committee, and was named Head of Global Commercial Operations in January 2025.

He has worked in various global leadership roles within the diagnostics industry during his career, and most recently served as Vice President and General Manager of the Genetic Testing Solutions Business at Thermo Fisher Scientific. Prior to this role, he spent over two decades at Siemens in commercial, strategy and finance roles, and in his last role as Global Head of the Molecular Diagnostics Business Unit at Siemens Healthineers.

He earned a degree in Business Administration from EWA Madrid and the University Mosbach School of Business.

QIAGEN Deep Dive – Sample technologies (2/2)



Justus Krause-Harder

Vice President

Head of Molecular Tools and Oncology

Justus Krause-Harder is Vice President and Head of Molecular Tools & Oncology at QIAGEN, where he is responsible for the global strategy and portfolio development across the company's oncology and molecular tools solutions. Since joining QIAGEN in 2014, he has held a series of senior leadership positions spanning regions and business areas, including Head of Marketing APAC, Head of QIAGEN Japan and Head of Life Sciences Sales Europe.

Mr. Krause-Harder brings over two decades of international experience in diagnostics and life sciences. Before joining QIAGEN, he held senior commercial leadership roles across multiple continents.

He studied Business Administration and Economics at Julius-Maximilians University of Würzburg and holds a Diploma in Business Administration with majors in Management, HR and Marketing from the East Asia Institute in Ludwigshafen, Germany.



Dr. Michael Scheffler

Vice President

Head of Sample Technologies

Michael Scheffler is Vice President and Head of Sample Technologies at QIAGEN, where he oversees the company's global Sample technologies portfolio. Since joining QIAGEN over 20 years ago, Dr. Scheffler has held various leadership roles in R&D, program and general management.

He has played key roles in the development and launch of several of QIAGEN's flagship platforms, including serving as R&D Lead for the QIAcube and Rotor-Gene Q and as Program Lead for the QIAcuity digital PCR platform. Since 2025, Dr. Scheffler has been responsible for driving the strategic direction and growth of QIAGEN's Sample prep solutions.

Dr. Scheffler holds a Master's degree and a PhD in Engineering from the Technical University of Berlin and ETH Zurich, respectively.